October 14
CUREator+ Opens Second Funding Round for Australian Biotech and Healthtech Innovators
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectThe Australian Institute of Tropical Health and Medicine (AITHM) is a multi-disciplinary health and tropical medicine research institute located in the tropics. Based at James Cook University in northern Queensland, AITHM has key nodes in Townsville, Cairns and the Torres Strait.
ViewThe Malaghan Institute of Medical Research is New Zealand’s leading independent biomedical research institute, with a history spanning over five decades. The Institute’s research centers on the immune system, and how it may be harnessed to treat human disease. Pioneering research programmes explore fields of immunotherapy such as cancer, asthma and allergy, infectious diseases, gut health and brain health.
ViewAITHM is a flagship research institute of James Cook University based in the tropics of northern Australia. Australia’s only dedicated tropical health and medicine research institute, AITHM is focussed on solving problems of importance to the tropics, leading to improvements in health systems and healthcare delivery, improved biosecurity, and enhanced health outcomes for Australians and our neighbouring tropical nations.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreCUREator+ Opens Second Funding Round for Australian Biotech and Healthtech Innovators
Read moreCerta Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Read moreBrandon BioCatalyst’s CUREator Incubator Boosts Preclinical and Health Security Biotech Innovations with $1.865m in funding.
Read moreENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral
Read more